Anti-FLT3 antibodies

Details Anti-FLT3 antibodies Anti-FLT3 antibodies

2010-09-27

2011-12-06

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S139100, C424S141100, C435S069100, C435S325000, C435S326000, C435S331000, C530S387900, C530S388100, C530S388230

Reexamination Certificate

active

08071099

ABSTRACT:
The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5548065 (1996-08-01), Lemischka
patent: 5635388 (1997-06-01), Bennett et al.
patent: 5777084 (1998-07-01), Buhring
patent: 6156882 (2000-12-01), Buhring et al.
patent: 6217866 (2001-04-01), Schlessinger et al.
patent: 322424 (1989-09-01), None
patent: 88/09344 (1988-12-01), None
patent: 89/09622 (1989-10-01), None
patent: 92/01047 (1992-01-01), None
patent: 92/17486 (1992-10-01), None
patent: 93/11236 (1993-06-01), None
patent: 93/21319 (1993-10-01), None
patent: 94/28391 (1994-12-01), None
patent: 95/07348 (1995-03-01), None
patent: 95/27062 (1995-10-01), None
patent: 98/25457 (1998-06-01), None
patent: 99/60023 (1999-11-01), None
patent: 02/102854 (2002-12-01), None
patent: 02/102973 (2002-12-01), None
patent: 05/094823 (2005-10-01), None
patent: 07/124221 (2007-11-01), None
patent: 08/153926 (2008-12-01), None
U.S. Appl. No. 07/679,666, filed Apr. 2, 1991, Lemischka; The Trustees of Princeton University.
Batley, et al., Life Sci. 62:143-150 (1998).
Burdon, et al., Eds., Laboratory Techniques in Biochemistry and Molecular Biology, vol. 13, Elsevier Science Publishers, Amsterdam (1985); Campbell, Monoclonal Antibody Technology, The Production and Characterization of Rodent and Human Hybridomas.
Burtrum, et al., Cancer Res. 63:8912-21 (2003).
Chothia, et al., J. Mol. Biol. 196 (4):901-917 (1987).
Coligan, et al. Current Protocols in Immunology, Wiley & Sons, Incorporated (1991).
Collins, Glia. 15:289-296 (1995).
Furukawa, et al. Leukemia 21:1005-1014 (2007).
Grandis, et al., Cancer 78:1284-1292 (1996).
Hawkins, et al., J. Mol. Biol. 226:889-896 (1992).
Hermentin, et al., Behring Inst. Mitt. 82:197-215 (1988).
Hoffmann, et al., Anticancer Res. 17:4419-4426 (1997).
Huse, et al., Science 246:1275-1281 (1989).
Jones, Genetics 85:23-33 (1977).
Kabat, et al., Ann. NY Acad. Sci. 190:382-393 (1971).
Kabat, et al., Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991).
Kaufmann, et al., J. Mol. Biol. 159:601-621 (1982).
Kingsman, et al., Gene 7:141-151 (1979).
Kohler, et al., Nature 256:495-497 (1975).
Lamoyi, et al., J. Immunol. Methods 56:235-243 (1983).
Li, et al., Blood 104(4):1137-1144 (2004).
Li, et al., Drug Devel. Res. 67(6):495-500 (2006).
Li, et al., Expert Opin. Biol. Ther. 7(3):319-330 (2007).
Li, et al., Int. J. Hematol. 82(2):108-114 (2005).
Low, et al., J. Mol. Biol. 250:359-368 (1996).
Nielsen, et al., Prot. Eng. 10:1-6 (1997).
Panek, et al., J. Pharmacol. Exp. Thera. 283:1433-1444 (1997).
Parham, J. Immunol. 131: 2895-2902 (1983).
Pearson, et al., Proc. Natl. Acad. Sci. USA 85:2444-2448 (1988).
Pedley, et al., Br. J. Cancer 68:69-73 (1993).
Petrides, et al., Cancer Res. 50:3934-3939 (1990).
Piloto, et al., Blood 109(4):1643-1652 (2007).
Piloto, et al., Cancer Res. 65(4):1514-1522 (2005).
Piloto, et al., Cancer Res. 66(9):4843-4851 (2006).
Radinsky, et al., Clin. Cancer Res. 1:19-31 (1995).
Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press (1989).
Sauter, et al., Am. J. Path. 148:1047-1053 (1996).
Scahill, et al., Proc. Nat'l Acad. Sci. 80:4654-4659 (1983).
Shimizu, et al., Japan J. Cancer Res. 85:567-571 (1994).
Shokri, et al., Appl Microbiol Biotechnol. 60:654-664 (2003).
Southern, et al., J. Mol. Appl. Genet. 1:327-341 (1982).
Stincomb, et al., Nature 282:39-43 (1979).
Stirewalt, et al., Nature Reviews Cancer 3:650-665 (2003).
Subramani, et al., Mol. Cell. Biol. 1:854-864 (1981).
Urlaub, et al., Proc. Nat'l Acad. Sci. 77:4216-4220 (1980).
Von Heinje, et al., Nucl. Acids Res. 14:4683-4690 (1986).
Wikstrand, et al., Cancer Res. 55:3140-3148 (1995).
Williams, et al., AACR annual meeting 2007 poster presented.
Williams, et al., Leukemia 19(8):1432-1438 (2005).
Yang, et al., J. Mol. Biol. 254:392-403 (1995).
Zheng, et al., Blood 103(1):267-274 (2004).
Relevant ClinicalTrials.gov information (last updated Feb. 8, 2011). http://www.clinicaltrials.gov/ct2/show/NCT00887926?term=EB10&rank=1.

Affiliated with

Also associated with

Rating

Anti-FLT3 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-FLT3 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-FLT3 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4262364